ReGenStent
A Stent That Grows With the Child
Problem: Conventional metal stents do not grow with children with congenital heart defects and require repeated interventions
Goal: A bioresorbable stent platform designed to keep the vessel open, then degrade in a controlled manner and thus allow the vessel to grow
Cardiology
ReGenStent in a Nutshell
Keeping vessels open, allowing growth
- Develops a bioresorbable stent specifically for children, including infants
- The stent is designed to keep the narrowed vessel open and then degrade in a controlled manner
- Computational models, imaging, and 3D printing are used to plan and manufacture the shape and size of the stents
In children with congenital heart defects, blood vessels can be narrowed, for example in the pulmonary arteries. Such narrowings may be congenital or develop as a result of previous heart surgery. The vessel is often kept open with a stent. However, conventional metal stents do not grow: as the child grows, they must be repeatedly dilated with a balloon or replaced. The research team led by Maximilian Y. Emmert is therefore developing a bioresorbable stent platform specifically tailored to the needs of children.
The stent is designed to first keep the vessel open and then degrade in a controlled manner. This should allow the vessel to regain its natural flexibility and continue to grow, while keeping later treatments possible. Using advanced computational models and imaging techniques, the researchers plan the shape and size of the stents and assess their behavior as blood vessels grow. The stents are manufactured using additive manufacturing (3D printing).
Over the next five years, the platform will be advanced to the point of first-in-human application. This includes stepwise optimization of the design, careful preclinical evaluation of safety and efficacy, and the establishment of a regulatory-compliant manufacturing process. In dedicated safety studies, the team investigates how stable the stents are in the bloodstream of growing children and how well they are tolerated by the body. The long-term goal is a first clinical study involving children in Zurich. The project starts in November 2026.
Significance for Medical Research
ReGenStent addresses a currently unmet medical need in pediatric cardiology and strengthens Zurich as a research hub at the intersection of bioengineering, regenerative medicine, and clinical care. A growth-adaptive, bioresorbable stent could potentially spare children repeated interventions and major heart surgery.
The project combines additive manufacturing, computational modeling, preclinical research, and clinical expertise, and brings together the University of Zurich, ETH Zurich, University Hospital Zurich, and University Children’s Hospital Zurich. In doing so, ReGenStent creates a sustainable translational pipeline for regenerative cardiovascular implants – from materials development to clinical application – positioning Zurich as an internationally visible center for precision medicine and translational healthcare innovation.
Cardiology
The Consortium

Maximilian Y. Emmert, University of Zurich, Institute for Regenerative Medicine.

Mamzi Afrasiabi, ETH Zurich, Department of Mechanical and Process Engineering.

Francesca Bonassin Tempest, University Hospital Zurich, Zurich Heart Center.

Alessia Callegari, University Children’s Hospital Zurich, Cardiology.

Melanie Generali, University of Zurich, Institute for Regenerative Medicine.

Oliver Kretschmar, University Children’s Hospital Zurich, Cardiology.

André Studart, ETH Zurich, Department of Materials.

Emanuela Valsangiacomo Buechel, University Children’s Hospital Zurich, Cardiology.